Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (XENE) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in the near term. However, absence of recent events does not eliminate underlying risk—the 90-day window captures only a fraction of the company's risk profile. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores, maps financing history, and applies AI risk signals to identify emerging concerns that may not yet appear in headlines. The full $49 Report adds comprehensive dilution trajectory, historical 8-K context, capital raise patterns, and machine-flagged anomalies across 12 months of data.